Is PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2014 still in force?

Yes — PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2014 is currently in force.

When did PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2014 take effect?

PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2014 was first recorded in 2014.

How many sections does PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2014 have?

PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2014 contains 2 sections.

Where can I read the official version of PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2014?

The official text of PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2014 is published at lom.agc.gov.my.

/akn/my/act/pua/2014/116

PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2014

The full official text, structured for quick navigation. Copy any provision or jump straight to a section.

Open source PDF

Type: P.U. (A)
Status: In force
Enacted: 2014
Sections: 2

Quick answer

About this p.u. (a)

PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2014 is Malaysia P.U. (A), cited as P.U. (A) 116 2014, currently marked in force and first recorded in 2014.

Opening note

Preamble

PADA menjalankan kuasa yang diberikan oleh seksyen 6 Akta Racun 1952 [Akta 366], Menteri, selepas berunding dengan Lembaga Racun, membuat perintah yang berikut: Nama

Seksyen 1

Perintah ini bolehlah dinamakan Perintah Racun (Pindaan Senarai Racun) (No. 2) 2014.

Seksyen 2

Pindaan Jadual Pertama

(a)

dalam Senarai Racun—

(i)

dengan memasukkan selepas butiran “Azelaic Acid” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Bahagian I

Part I

Bahagian II

Part II

Exempt

Group A

Group B

Group C

Group D

“Azilsartan

All preparations”;

(ii)

dalam butiran “Antihistamines; the following:”, dengan memasukkan selepas butiran “Bamipine” butiran

“Bilastine”;

(iii)

dengan memasukkan selepas butiran “Dantrolene; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Dapagliflozin

All preparations”;

(iv)

dengan memasukkan selepas butiran “Dolasetron Mesylate” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Dolutegravir

All preparations”;

(v)

dengan memasukkan selepas butiran “Lithium salts for therapeutic use” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Lixisenatide

All preparations”;

(vi)

dengan memasukkan selepas butiran “Minoxidil; its salts; its derivatives” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Mipomersen sodium

All preparations”;

(vii)

dengan memasukkan selepas butiran “Nystatin” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Ocriplasmin

All preparations”;

(viii)

dengan memasukkan selepas butiran “Octreotide; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

(ix)

dengan memasukkan selepas butiran “Pentoxifylline” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Perampanel

All preparations”;

Names

Exempt

Group A

Group B

Group C

Group D

“Ofatumumab

All preparations”;

(x)

dalam butiran “Racecadotril”, dengan menggantikan “Racecadotril” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Racecadotril

All preparations”; dan

(xi)

dengan memasukkan selepas butiran “Vigabatrin” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Vilanterol

All preparations”; dan

(b)

dalam Lampiran Senarai Racun—

(i)

dalam senarai “Antineoplastic agents and Immunosuppressants:”, dengan memasukkan selepas butiran

“Octreotide” butiran “Ofatumumab”;

(ii)

dalam senarai “Anti-asthmatics:”, dengan memasukkan selepas butiran “Tulobuterol” butiran “Vilanterol”;

(iii)

dalam senarai “Anticonvulsants:”, dengan memasukkan selepas butiran “Paramethadione” butiran “Perampanel”;

(iv)

dalam senarai “Antidiabetics:”—

dengan memasukkan selepas butiran “Chlorpropamide; its salts” butiran “Dapagliflozin”; dan

(B)

dengan memasukkan selepas butiran “Liraglutide” butiran “Lixisenatide”;

(v)

dalam senarai “Antihistamines:”, dengan memasukkan selepas butiran “Bamipine” butiran “Bilastine”;

(vi)

dalam senarai “Antihypertensives:”, dengan memasukkan selepas butiran “Aliskiren” butiran “Azilsartan”;

(vii)

dalam senarai “Antiviral agents:”, dengan memasukkan selepas butiran “Didanosine” butiran “Dolutegravir”; dan 9

(viii)

dalam senarai “Miscellaneous:”—

dengan memasukkan selepas butiran “Metyrapone; its salts” butiran “Mipomersen sodium”; dan dengan memasukkan selepas butiran “Nux Vomica, alkaloids of” butiran “Ocriplasmin”.

Dibuat 9 April 2014

[KK(R)608(14); PN(PU2)172/XII]

DATUK SERI DR. S. SUBRAMANIAM

Menteri Kesihatan

POISONS ACT 1952

POISONS (AMENDMENT OF POISONS LIST) (NO. 2) ORDER 2014

Opening note

Preamble

IN exercise of the powers conferred by section 6 of the Poisons Act 1952 [Act 366], the Minister, after consultation with the Poisons Board, makes the following order: Citation 1. This order may be cited as the Poisons (Amendment of Poisons List) (No. 2) Order 2014. Amendment of First Schedule 2. The Poisons Act 1952 is amended in the First Schedule—

(a)

in the Poisons List—

(i)

by inserting after the item “Azelaic Acid” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Azilsartan

All preparations”;

(ii)

under the item “Antihistamines; the following:”, by inserting after the item “Bamipine” the item “Bilastine”;

(iii)

by inserting after the item “Dantrolene; its salts” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Dapagliflozin

All preparations”;

(iv)

by inserting after the item “Dolasetron Mesylate” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Dolutegravir

All preparations”;

(v)

by inserting after the item “Lithium salts for therapeutic use” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Lixisenatide

All preparations”;

(vi)

by inserting after the item “Minoxidil; its salts; its derivatives” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Mipomersen sodium

All preparations”;

(vii)

by inserting after the item “Nystatin” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Ocriplasmin

All preparations”;

(viii)

by inserting after the item “Octreotide; its salts” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Ofatumumab

All preparations”;

(ix)

by inserting after the item “Pentoxifylline” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Perampanel

All preparations”;

(x)

in the item “Racecadotril”, by substituting for “Racecadotril” and the particulars relating to it the following particulars:

Names

Exempt

Group A

Group B

Group C

GroupD

“Racecadotril

All preparations”; and

(xi)

by inserting after the item “Vigabatrin” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Vilanterol

All preparations”; and

(b)

in the Appendix to the Poisons List—

(i)

in the list of “Antineoplastic agents and Immunosuppressants:”, by inserting after the item “Octreotide” the item “Ofatumumab”;

(ii)

in the list of “Anti-asthmatics:”, by inserting after the item “Tulobuterol” the item “Vilanterol”;

(iii)

in the list of “Anticonvulsants:”, by inserting after the item “Paramethadione” the item “Perampanel”;

(iv)

in the list of “Antidiabetics:”—

by inserting after the item “Chlorpropamide; its salts” the item “Dapagliflozin”; and by inserting after the item “Liraglutide” the item “Lixisenatide”;

(v)

in the list of “Antihistamines:”, by inserting after the item “Bamipine” the item “Bilastine”;

(vi)

in the list of “Antihypertensives:”, by inserting after the item “Aliskiren” the item “Azilsartan”;

(vii)

in the list of “Antiviral agents:”, by inserting after the item “Didanosine” the item “Dolutegravir”; and

(viii)

in the list “Miscellaneous:”—

by inserting after the item “Metyrapone; its salts” the item “Mipomersen sodium”; and by inserting after the item “Nux Vomica, alkaloids of” the item “Ocriplasmin”.

Made 9 April 2014

[KK(R)608(14); PN(PU2)172/XII]

DATUK SERI DR. S. SUBRAMANIAM

Minister of Health

Common questions

What is PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2014?: PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2014 is Malaysia P.U. (A), cited as P.U. (A) 116 2014, currently marked in force and first recorded in 2014.
Is PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2014 still in force?: Yes — PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2014 is currently in force.
When did PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2014 take effect?: PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2014 was first recorded in 2014.
How many sections does PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2014 have?: PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2014 contains 2 sections.
Where can I read the official version of PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2014?: The official text of PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2014 is published at lom.agc.gov.my.